A Phase Ib/IIa Two-part, Randomized, Placebo-controlled, Observer-blind, Dose-finding Evaluation Trial to Describe the Safety, Reactogenicity, and Immunogenicity of Two Investigational Vaccines Against Tuberculosis in BCG Vaccinated, HIV-negative Subjects and People Living With HIV
Latest Information Update: 10 Jul 2025
At a glance
- Drugs BNT 164 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors BioNTech
Most Recent Events
- 27 Apr 2025 Planned number of patients changed from 732 to 492.
- 24 Mar 2025 Status changed from active, no longer recruiting to recruiting.
- 13 Jan 2025 Planned primary completion date changed from 1 May 2026 to 1 Jun 2026.